Operator

Good day, and welcome to the Hansa Biopharma First Quarter 2026 Earnings Results Conference Call. [Operator Instructions] This event is being recorded. I would now like to turn the conference over to Hansa Biopharma's CEO, Renee Aguiar-Lucander. Please go ahead.

Renee Aguiar-Lucander
Chief Executive Officer

Thank you very much. Good afternoon, and good morning, everybody, and welcome to Hansa Biopharma's conference call to review the Q1 results for 2026. I'm Renee Aguiar-Lucander, CEO for Hansa Biopharma. And joining me today is Evan Ballantyne, Chief Financial Officer; Richard Philipson, Chief Medical Officer; and Maria Tornsen, Chief Operating Officer and President of the U.S. Please -- next slide, please. Please allow me to draw your attention to the fact that we'll be making forward-looking statements during the presentation. You should therefore apply appropriate caution. Next slide, please.

This is the agenda for today's call, and these are the people who will, as I just mentioned, who will be covering the different sections. Next slide, please. So let me start by taking you through an overview of the quarter. As I mentioned in the Q4 report, we expected Q1 to be impacted by the significant number of initiatives, which we rolled out during the quarter, which I'll cover in some more detail later